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ABSTRACT 
QUANTITATIVE ESTIMATION OF HEPARIN CONTENT ON BIOLOGICAL 
PERICARDIUM TISSUE USING IN VITRO ANTI-FACTOR Xa ASSAY 
by 
Jean-Claude Simeon 
Shelhigh Inc. (Millburn, NJ) has developed a new heparin binding technique to 
biological tissues. The technique seems to bind heparin to tissues in a more permanent 
fashion. Shelhigh's heparinized biological tissues are intended for use in long term 
implants. This investigation was undertaken to assess whether heparin leaching is 
prevalent when tissues are quarantine for long shelflife at room temperature, whether 
tissues maintained thromboresistance properties when in contact with plasma and to 
estimate heparin content of the tissues. 
The study used anti-factor Xa assaying methods: clotting time and chromogenic 
factor Xa sensitive substrate in order to fulfill the aforementioned objectives. Anti-factor 
Xa assay was chosen because of its specificity. It characterized the role of heparin in the 
inactivation of factor Xa. Storage solutions containing heparinized pericardium tissues 
were mixed with equal volume of plasma in order to assess for heparin leaching. The 
average clotting time for these solutions was 22+/-.50 seconds. This result was in the 
range of clotting time of zero unit heparin in plasma. When Shelhigh's heparinized 
pericardium tissues were exposed to plasma at 37°C , neutralization of clotting factor 
Xa was accelerated as measured by the clotting time and chromogenic substrate method, 
and this was attributed to trace amounts of heparin released from the pericardium tissues. 
This demonstrated that Shelhigh's pericardium tissues have thromboresistance properties 
when in contact with plasma. 
To estimate the heparin content on the pericardial tissues, conventional methods 
used to estimate heparin content on material surfaces was not applied. 	In this 
investigation, heparin is not immobilized on the tissue surfaces. Rather, the heparin is 
attached onto the matrix of the tissues. Therefore, to estimate heparin content on 
heparinized pericardium tissues, the tissues had to be dried, ground and incubated in 
plasma at 37'C . The estimated heparin content measured on tissue samples according 
to the clotting time and chromogenic substrate was observed to be varying, although all 
of the tissues were heparinized using standard manufacturing procedures. 
The contribution of heparin released from Shelhigh's heparinized biological 
pericardium tissues stored in storage solution at room temperature was found to be 
negligible. When the tissues were in contact with plasma, neutralization of clotting 
factor Xa increased dramatically. Therefore, it can be concluded that heparin from 
Shelhigh's pericardium tissues markedly improves thromboresistance properties. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background Information 
Heparin is a sulfated glycoaminoglycan mixture, composed of repeating monosaccharide 
units of L-iduronic and glucosamine (Figure 1) (1). Due to its structure and surface 
charge, heparin is able of interacting with several blood clotting factors in a specific 
manner (9). Heparin is widely used as an anticoagulant that aids in the circulation of 
blood in patients. 	In addition, it has been used in extracorporeal devices (i.e. 
hemodialysis, surgical procedures and/or heart-lung machines) and for biological tissues 
other than the natural endothelial lining wall to procure thromboresistance properties. 
Experiments have shown that the blood compatibility properties of bound heparin behave 
in similar manner to that of the fluid phase. That is, like heparin in solution, bound 
heparin accelerated the inactivation of thrombin and factor Xa by antithrombin-dependent 
mechanism (2-7). 
The finding that bound heparin exerts similar anticoagulant activity to that in 
solution has led to several hypothetical mechanisms about the fates of bound heparin 
(Table I). For example, when heparin is released from a surface, there exist a heparin 
microenvironment at the material/blood interface to impart thromboresistance properties 
(4). 
Figure 1. Heparin Structure 
Heparin is a linear polysaccharides mixture composed of repeating units of L-Iduronic 
acid and D-glucosamine. [A] is the most common disaccharide unit, representing 90 % of 
the beef-lung structure, and up to 70% pig-mucosa heparin. [B] is a unique 
pentasaccharride binding site for antithrombin. 
Taken from (1, p.4 ) by Chromogenix Monograph Series 
Table I. Conceivable Fates of Surface-Bound Heparin 
• Bound heparin is released creating a heparin microenvironment at the material/blood 
interface. 
• Bound heparin remains attached to the material, but becomes saturated with inactive 
complex. 
• Heparin acts catalytically and does not become saturated, but a high production of 
inactive complex causes a systemic hypocoagulability. 
• Heparin does not become saturated, and inactive complex formation is maintained to 
within tolerable levels. 
Taken from (4, p.149) by M.F.A Goosen and M. V. Sefton 
The anticoagulant activity of heparin is characterized by its interaction with 
antithrombin III, the primary inhibitor in the blood coagulation system. Antithrombin III 
inactivates thrombin by forming an irreversible-antithrombin III complex. In addition, 
antithrombin III inactivates several serine proteases clotting factors, namely factors XIIa, 
XIa, IXa, and Xa. However, of all the blood coagulation proteases, only the antithrombin 
III dependent-mechanism of thrombin and factor Xa is effectively inhibit (2,3,7). The 
inhibitory capacity of antithrombin III is enhanced in the presence of heparin. Heparin 
accelerated the rate of formation of irreversible complexes between antithrombin III and 
thrombin and factor Xa. Heparin inactivates thrombin and factor Xa by antithrombin III 
bound to end-point attachment mechanism (Figure 2) (1,9). 
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The accelerating function of heparin depends on a highly specific antithrombin-binding 
pentasaccharide sequence of the heparin molecule. 	Binding to this pentasaccharide 
sequence causes a conformational change in antithrombin III that increases the anti-
thrombin and anti-factor Xa activity several folds. In addition, the effect of heparin on 
the reaction between antithrombin III and thrombin require the heparin chain to be of a 
certain length (> 18 monosaccharides). The inactivation of factor Xa, on the other hand, 
can be achieved by very small heparin chain length (>5 monosaccharides) (1,9). Despite 
the facts mentioned above, the elucidated mechanism between heparin and antithrombin 
III is open to debate. There exist two prevalent opinions about the mode of heparin 
action with antithrombin III. First, heparin (Table II) is thought to react with thrombin 
producing a conformational change in thrombin causing a rapid complex formation with 
antithrombin III (Figure 2). The alternative mechanism, proposed that heparin binds to 
antithrombin III, inducing a conformational change that convert antithrombin III from a 
slow inhibitor to a very fast inhibitor (1-7). The heparin-antithrombin III complex then 
inhibits several coagulation proteases, which included factors IXa, Xa, XIa, 
thrombin and as well as plasmin and kallikrein, supporting the heparin to antithrombin III 
mechanism (Figure 3). However, there are numerous experiments or results that favored 
the thrombin-heparin mechanism (2,13). 
Table II. Mechanisms for Inactivation of an Enzyme by Inhibitor in the Presence of 
Activator 
• Heparin binds to enzyme (Thrombin or Factor Xa) to make it more susceptible to 
antithrombin. 
• Heparin reacts with the enzyme-inhibitor complex and accelerates the formation of a 
covalent bond between enzyme and inhibitor. 
• Heparin activates antithrombin to make it a more potent/ faster inhibitor 
Taken from [13, p.838] by J. Sturzebecker and F. Markwardt 
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Figure 2. Model Describing How Heparin Catalyzes the Antithrombin-Protease Reaction 
[H] represents the heparin binding site and [R] is the reactive site in the antithrombin and 
[P] is the unique antithrombin sequence binding sequence of heparin,. Binding to this 
sequence causes a conformational change in antithrombin, which enhanced reaction with 
it proteases target. Top: Demonstrated the effect of heparin on the reaction between 
antithrombin (Ha), the heparin which must be of certain length (> 18 monosaccharides) 
reacts with enzyme-inhibitor complex to accelerate the formation of covalent bond 
between enzyme and inhibitor. Thrombin binds nonspecifically and slides along until 
encounter the bound antithrombin. Bottom: Inactivation of factor Xa does not require 
ternary complex formation and is achieved solely through antithrombin binds to heparin. 
Taken from (1, pp.7) by Chromogenix Monograph Series 
Figure 3. Coagulation Cascade. Blood coagulation is an enzymatic event initiated in 
response to tissue damage and introduction of foreign materials other than the natural 
endothelial lining. Heparin, an anticoagulant agent inhibits blood from clotting primarily 
by its binding to antithrombin, thereby accelerating the inhibition of Xa and thrombin in 
plasma. Taken from (1, pg. 4) by Chromogenix Monograph Series. 
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The finding that bound heparin exerts anticoagulant effect similar to that of fluid 
phase has led to numerous studies to alter implantable artificial material (i.e. polymers 
and biological tissues) in order to deem them blood compatible properties. Researchers 
typically take two approaches in modifying foreign biomaterials: modification of foreign 
biomaterials surface, in which preexisting materials are altered or new materials are 
produced with properties that procure thromboresistance, or the pharmaceutical approach, 
in which anticoagulant agents (e.g. heparin) are applied along with the materials (9,12). 
Heparinization of foreign biomaterials has been achieved by two well-established 
methods: covalent and ionic bonding. Covalent end-point attachment of nitrite degraded 
heparin on artificial biomaterials procures good thromboresistance properties to foreign 
biomaterials, without systemic anticoagulant treatments (2,3,5). Ionic bonding involves 
formation of quaternary amine groups onto biomaterial surface into which negatively 
charged heparin can be attach. Heparinization treatment of foreign biomaterials prepared 
by ionic coupling also procured good blood compatibility properties to biomaterial 
surfaces. However, due to heparin's rapid removal rate from the biomaterials, this 
approach is rendered to be unsuitable for long-term implants (2,3). Shelhigh Inc. 
(Millburn, NJ) has developed a new heparin binding technique to biological tissues. The 
technique seems to bind heparin to tissues in a more permanent fashion. Shelhigh's 
heparinized biological tissues were able to prolong in vitro clotting times, and extend the 
blood biological patency when in vivo. This study was intended to evaluate the 
biological activity of heparin bound to biological pericardium tissues. 
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1.2 Objectives 
In light of the facts aforementioned, the following objectives for the present investigation 
were set: 
1. To assess whether heparin is released from heparinized biological pericardium 
tissues into storage solution (2 % benzyl alcohol) during long shelf life. 
2. To assess whether heparinized biological pericardium tissues have 
anticoagulant properties when in contact with plasma. 
3. To quantitatively estimate heparin content in heparinized biological 
pericardium tissues. 
This study used anti-factor Xa assays: clotting time assay introduced by Yin et al. 
(20) and a chromogenic factor Xa sensitive substrate assay introduced by Teien et al. 
(18). The anti-factor Xa assay was chosen because of its specificity. It characterized the 
ability of heparin-accelerated antithrombin to inactivate clotting factor Xa. The clotting 
time assay introduced by Yin et al. is based on heparin catalyst activity to accelerate the 
neutralization of factor Xa. Then, a clotting time technique (i.e. Fibrometer) is used to 
measure the residual factor Xa. The chromogenic factor Xa sensitive substrate assay is a 
photometry version of anti-factor Xa. The assay used a synthetic factor Xa sensitive 
substrate to measure the residual factor Xa, which correspond to a heparin concentration 
present in a testing sample. 
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This study used the aforementioned assays to determine whether heparin is 
leached from She'high's biological pericardium tissues when quarantined for a long 
shelflife; whether heparin from biological pericardium tissues is biologically active when 
in contact with plasma; and to quantitatively estimate the heparin content in biological 
pericardium tissues. This investigation was performed at Shelhigh Inc. (Millburn, NJ) 
facilities. 
CHAPTER 2 
MATERIALS AND EXPERIMENTAL METHODS 
2.1 Materials 
Saline 0.9 gram sodium chloride dissolved in 100 ml distilled water to make a 0.9 (w/v) 
% saline solution. Used to dilute concentrated heparin. 
Heparin. A highly sulfated polysaccharide derived from porcine intestines (Elkins Sinn, 
Inc., Cherry Hill, NJ, lot no. 106080), 5000 Units/ml diluted in 0.9 (w/v)% saline solution 
to 100 Units/ml. Heparin is anticoagulant when combines with antithrombin III increases 
the effectiveness of antithrombin III from a hundred-to-a thousandfold in neutralizing 
thrombin and factor Xa. 
Acetic acid 3 M or 20 % acetic acid. Used to stop reaction in the chromogenic factor Xa 
sensitive substrate assay (end-point method). 
Fresh Frozen Plasma. Collected and processed by the Blood Bank Center of New Jersey 
Inc., E. Orange, NJ. Obtained from the University of Medicine and Dentistry of New 
Jersey (Newark, NJ) blood bank. 




2.2 Anti-factor Xa Clotting Time Assay Reagents 
Bovine Factor Xa. Catalog No. F 3649 (SIGMA DIAGNOSTICS) 
Lyophilized bovine Factor Xa reconstituted with 2 ml distilled water according to the 
manufacturer instructions contains bovine serum albumin, sodium chloride, PEG and tris-
maleate pH 7.5. The factor Xa is neutralized when incubate in heparinized plasma. The 
residual factor Xa is measured using a Fibrometer to measure the time it takes for plasma 
to clot. The amount of factor Xa neutralized is proportional to the heparin concentration 
present in the coagulation reaction mixture. 
RECALMIX. Catalog No. R0887 (SIGMA DIAGNOSTICS) 
Lyophilized rabbit brain cephalin with buffer reconstituted with 2 ml distilled water 
according to the manufacturer instructions, contains calcium chloride and bovine plasma 
fraction rich in fibrinogen and factor V, pH 7.5. This mixture contained maximum 
concentration of calcium chloride and brain cephalin in bovine plasma fraction, used to 
recalcify a reaction mixture after a predetermined incubation period. 
2.3 Anti-factor Xa Chromogenic Assay Reagents 
Bovine Factor Xa. Catalog No. B 4031 (SIGMA DIAGNOSTICS) 
Lyophilized bovine Factor Xa contains approximately 20 nKat/vial with 0.1% sodium 
azide as preservative, reconstituted with 5 ml distilled water according to the 
manufacturer instructions. The neutralization of factor Xa in the chromogenic assay is 
based on the same principle as described above. However, the residual factor Xa is 
measured using a synthetic factor Xa chromogenic substrate. 
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Human Antithrombin III. Catalog No. F3524 (SIGMA DIAGNOSTICS) 
Lyophilized preparation, when reconstituted with 5 ml distilled water contains human 
antithrombin III, 0.5 units/vial, tris-HCI, 0.05 M, sodium chloride, 0.175 M, EDTA, 7.5 
mM, pH 8.4 and 0.1 % sodium a7ide as preservative. The addition of antithrombin II 
helped to reduce the effect of varying antithrombin II concentrations in the assay. 
Factor Xa Substrate MeO-CO-D-CHG-Gly-Arg-pNA. Catalog No. F 3524 (SIGMA 
DIAGNOSTICS) 
Lyophilized MeO-CO-D-CHG-Gly-Arg-pNA, reconstituted with 5 ml-distilled water 
according to the manufacturer instructions. The factor Xa substrate is used to measure 
the residual factor Xa. When incubated with factor Xa, the paranitroaniline (pNA) 
attached to the end is cleaved and a yellow color is observed. The yellow color is 
inversely proportional to the heparin concentration present in the reaction mixture. 
2.4 Instruments 
Spectrophotometer 405 nm, Shimadzu Scientific Instruments, Inc. (7120 Riverwood 
Drive, Columbia, Maryland, 21046 USA). 
Fibrometer BBL Fibrometer, Precision Coagulation Timer (Becton Dickinson 
Microbiology System, 250 Schilling Circle, Cockeysville, Maryland 21030 USA). 
Heating device Precision, Molecular Biology Waterbath Model 180 
Grinder Braun Grinder, KSM2, Model 4041 
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2.5 Experimental Methods 
2.5.1 Preparation of Standards 
2.5.1.1 Anti-factor Xa Clotting Time Assay: This method is based on the principle of 
incubation activated factor Xa with plasma at 37C. A RECALMIX solution, which 
contained brain cephalin, calcium chloride and bovine plasma fraction rich in fibrinogen 
and factor V, pH 7.5 is then added to the reaction mixture. The time it takes (i.e. 
seconds) for the plasma mixture to clot is recorded using a Fibrometer and converted to 
units heparin per ml plasma using the prepared standard curve. The presence of heparin 
in the reaction mixture prolonged the clotting time by neutralizing the factor Xa in the 
incubation mixture. The neutralization of clotting factor Xa is directly proportional to the 
heparin content present in testing plasma (17, 20). 
The assay in detailed is composed of pre-warming the RECALMIX mixture for at 
least 5 minutes at 3T C. Then, 1004 of test plasma or standard plasma is added to a 
pre-warm coagulation reaction cuvet and incubated for 2 minutes at 3T C After the 
incubation, 1004 factor Xa is added to the coagulation reaction cuvet and mixed 
thoroughly. After exactly 2 minutes, the mixture is transferred to a warm coagulation 
fibrotube cup containing 1004 RECALMIX mixture and clotting time is recorded using 
the BBL Fibrometer, Precision Coagulation Timer (Becton Dickinson Microbiology 
Systems, 250 Schilling Circle, Cockeysville, Maryland 21030 USA). 	Clotting time 
(seconds) is recorded and converted to units heparin per ml plasma using the established 
heparin standard curve. Tests were performed in duplicates and the results averaged. 
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When clotting time for a run was more than 10% higher than the shorter clotting time (or 
vice-versa), a third clotting time trial was performed. Test samples, that gave clotting 
times outside normal range of the standard curve, were diluted with plasma in 1 in 2, 1 in 
3, 1 in 5, or 1 in 10, or with respect to the anticipatory heparin concentration (20). 
In order to obtain accurate and reproducible results using the Fibrometer system, 
the following recommendations were considered: (1) Prewarmed the RECALMIX for 
exactly five minutes according to the manufacturer instructions. (2) Incubate test plasma 
or standard plasma and factor Xa together for exactly two minutes. (3) Prewarmed the 
coagulation reaction cuvet. (4) Clean the Fibrometer probe between run. 
2.5.1.2 Anti-Factor Xa Chromogenic Substrate Assay: The present assay analyzed 
heparin as a complex of heparin-antithrombin III (Table III). The assay involved 
incubating test plasma or standard plasma with excess factor Xa. Some of the factor Xa 
is neutralized by the Heparin-ATIII complex in relative proportion to the concentration of 
heparin present (1). The remaining factor Xa cleaves paranitroaniline (pNA) from a 
factor Xa specific chromogenic substrate (MeO-CO-D-CHG-Gly-Arg-pNA). 
The assay in details involved mixing 25µL test plasma or standard plasma with 
2004 human antithrombin III. The mixture is then incubated for 2 minutes at 37°C . 
After the incubation, 2004 bovine factor Xa is added to the reaction vessel, solution is 
mixed and incubated for exactly 60 seconds at 3T C . After exactly 60 seconds, 2004 
factor Xa substrate was pippeted to the reaction vessel and thoroughly mixed. 
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The reaction mixture is then incubated for exactly 5 minutes at 37°C . 	After the 
incubation, 200p  T of glacial acetic acid is then added into the reaction vessel to stop the 
reaction (end-point method). The absorbance of the mixture is read spectrophometrically 
at 405 nm against a blank reagent sample. The absorbance measured decreased linearly 
with increasing heparin concentration in the samples. The absorbance of a test sample 
was compared to the appropriate prepared standard curve to yield a corresponding units 
of heparin per ml plasma. Absorbance was recorded using Shimadzu UV 160U, UV-VIS 
Recording Spectrophotometer (Shimadzu Scientific Instruments, Inc., 7102 Riverwood 
Drive, Columbia, Maryland 21046 USA). To obtain accurate and reproducible results the 
following recommendations were taken into considerations: ( 1) Used proper pipetting 
technique and devices. (2) Adhered to incubation times and incubation temperature (i.e. 
37°C). 
Plasma heparin concentrations for the preparation of the standard curves were 
prepared by diluting 5000 Units/ml heparin to 100 Units/mL in 0.9% saline solution. 
9004 normal human plasma was mixed with 100µL of 100 U/mL heparin to give 10 
U/ml solution. 1004 of the 10 U/mL solution was mixed with 9004 normal human 
plasma to give a 1 Units/mL concentration. Standard curves were produced for each in 
vitro assay for solution heparin concentrations of 0.0, 0.125, 0.250, 0.500 units per mL 
plasma. The heparin used to prepare the standard curves came from a single lot. 
Table III. The Measurement Principle of the Chromogenic Substrate Assay 
Heparin + ATIII (excess)→ [Heparin*ATIII] 
[Heparin*ATIII] + FXa (excess)→ [Heparin*ATIII*FXa] + FXa (residual) 
FXa Substrate + FXa (residual) → Peptide + pNA 
Taken from IL p. 17] by Chromogenix Monograph Series 
17 
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2.5.2 Stability of Heparin in Biological Pericardium Tissues 
Four vials each contained 20-mL saline solution and 5x5 heparinized tissues were stored 
under sterile conditions at room temperature. 400µL of the storage solution from each 
vial was withdrawn every other week and tested for the amount of heparin released from 
the tissues. After three weeks of storage, the 5x5 heparinized tissue from each vial was 
withdrawn from the saline solution and washed with PBS (Phosphate-buffered saline) pH 
7.4. Two pieces were then dried in an oven overnight at 60°CC and later homogenized 
with normal human plasma. The other pieces were placed in 20-mL normal human 
plasma and incubated for 8 days in a water bath at 37°CC . 4004 of the incubated 
plasma was withdrawn every day and tested for heparin released using the standard 
methods. 
Samples of storage solution ( 2 % benzyl alcohol) containing heparinized 
biological pericardium tissues were also tested. These samples solution were subjected to 
standard assays to quantify heparin leakage during long shelflife. The solutions were 
taken from different year of manufacturing period. Some of these samples have been 
quarantined or remained in shelf for more than three years. To quantify heparin leakage 
from heparinized biological pericardium tissues in storage solution during shelflife, 
4004 of the storage solution was withdrawn and mixed with equal volume of normal 
human plasma. 
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2.5.3 Estimation of Heparin Content in Biological Pericardium Tissues 
Heparinized and non-heparinized biological (served as control) tissues were removed 
from storage solution ( 2 % benzyl alcohol) and washed with PBS, pH 7.4. The tissues 
were then placed into an oven to dry overnight at 60 C for 2-3 days. After the tissues 
were dried, they were ground in a grinder (Braun Grinder, KSM2, Model 4041) for 
twenty minutes or until tissues are finely ground. The ground tissues were weighed and 
placed into a test tube containing 4-mL normal human plasma. The mixture was mixed 
and allowed to incubate in water bath at 37°C for a 4 hours period, with frequent stirring 
to enhance the diffusion of heparin from the tissues. After the incubation, plasma was 
pippetted into a cuvet, which were subsequently tested for heparin using the in vitro 
chromogenic factor Xa substrate and clotting time assays as described above. 
In some cases, a small amount of grinding tissue was weighed and homogenized 
with 400µL normal human plasma. The mixture was then allowed to incubate for 4 
hours period, with frequent stirring at 3T C . After the incubation, 40µL. factor Xa was 
added and incubated for an additional 2 minutes according to standards preparation. 
20µL of the mixture was withdrawn and mixed with 1004 RECALMIX and recorded 
clotting time. 
Similarly, a small amount of ground tissue was weighed and incubated as above. 
After the incubation, human antithrombin III, bovine factor Xa, factor Xa substrate and 
acetic acid were added in the same time period as in the preparation of standards. 
CHAPTER 3 
RESULTS AND DISCUSSIONS 
3.1 Standard Curves for the Anti-factor Xa Assays 
Heparin was added in vitro to plasma in order to prepare standard curves. In the anti- 
factor Xa clotting time method, clotting time increased linearly with increasing heparin 
concentration in the standards (see Figure 4). 	That is, the amount of factor Xa 
neutralized is proportional to heparin concentration in standards or test plasma. For the 
chromogenic factor Xa substrate method, there is a linear relation between absorbance 
and heparin concentration in the standards (see Figure 5). Absorbance is inversely 
proportional to the heparin concentration in standards or test plasma. 
The minimum detectable heparin concentration for the clotting time and 
chromogenic factor Xa substrate method was 2.302 E-2 and 2.9157 E-2 units heparin per 
mL plasma, respectively. The clotting time method was set to provide a zero heparin 
clotting time of 18 +/-2.0 seconds. 
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Figure 4: Standard Curve for Anti-factor Xa Clotting Time Assay 
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Figure 5: Standard Curve for the Chromogenic Factor Xa Substrate Assay 
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3.2 Stability of Heparin in Biological Pericardium. Tissues 
The released of bound heparin from pericardium tissues in saline solution during the three 
weeks storage is negligible so as to be of no concern. Heparin concentration measured in 
saline solution is so low that it can be assumed to be zero. Furthermore, heparin 
concentration remained fairly constant with time as indicated by Figure 6. The average 
clotting time measured for the overall three weeks storage was 20.0+1-1.0 seconds. The 
approximate heparin content measured in the solution for the storage period allowed 
using the clotting time and chromogenic substrate was 2.898E-3+/-0.0009 and 3.2961E-
3+1-0.0005 units heparin per mL saline solution (n=21). Thus, it was concluded that 
heparin from biological pericardium tissues leached very little or not at all into the 
storage solution. 
Storage solutions that contained heparinized biological pericardium tissues for 
more than three years shelflife were also tested to determine whether heparin is released 
from the biological tissues. 	The average heparin concentrations measured for the 
solutions using the clotting time and chromogenic factor Xa substrate method was 
1.536E-2+/-0.00 and 1.526E-2+/-0.00 units heparin per mL storage solution . The 
average clotting time measured for these solutions 22.0+/-0.52 seconds (n=25). This 
result confirmed that the heparin content measured in solutions stored for the three weeks 
at room temperature. In addition, it showed that heparin does not leached from 
Shelhigh's heparinized biological pericardium tissues when quarantined for long shelflife. 
Thus, Shelhigh's heparinized pericardium tissues when implanted should have extended 
blood compatible efficacy. 
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Figure 6: Heparin Released from Pericardium Tissues Stored at Room Temperature 
for 21 Days 
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The amount of heparin released from the heparinized biological pericardium 
tissues when incubated in plasma at 37°C C is higher in comparison to tissues incubated in 
storage solution at room temperature (Figure 7). This result is consistent with 
expectation, when heparinized biological pericardium tissues are in contact with plasma 
at 37°CC heparin should be released from the tissues creating a heparin 
microenvironment, thus prevent the plasma from clotting. 
The incubated plasma containing the heparinized pericardium tissues neutralized 
factor Xa according to the clotting time and chromogenic factor Xa substrate assay. This 
indicated that heparin was indeed released from the pericardium tissues into the plasma. 
Furthermore, it indicated that the heparinized pericardium tissues have anticoagulant 
properties when in contact with plasma. Heparin concentration in plasma during the 
incubation period increased rapidly then appeared to stabilize (Figure 7). In time, it is 
expected for heparin to be released slowly from the pericardium tissues to create a 
heparin microenvironment at the material/plasma interface to impart thromboresistance 
characteristics. The percentage change of heparin concentration for the incubation period 
allowed was measured for the clotting time and chromogenic substrate factor Xa assay to 
be 10.6% and 9.97% respectively. The approximate heparin concentration measured in 
plasma using the clotting time and chromogenic substrate assay was.1415+/-.007 and 
.1479 +/-.0365 units heparin per ml plasma (n=6) respectively. 




3.3 Estimation of Heparin Content in Biological Pericardium Tissues 
The prolongation of clotting time caused by the addition of ground heparinized 
pericardium tissues to plasma is in contrast to plasma to which non-heparinized ground 
tissues have been added. 	The present investigation demonstrated that factor Xa is 
neutralized by heparin from the ground heparinized pericardium tissues for the incubation 
period allowed. 	In the estimation of heparin content on heparinized biological 
pericardium tissues, the loss of factor Xa was observed to increase when the pericardium 
tissues are finely ground, and this was observed to vary from tissue to tissue, although all 
of the tissues used for the study were pericardium. The average clotting time measured 
for plasma with non-heparinized pericardium tissues was 26+/-2.0 seconds. This clotting 
time value gave heparin concentration in plasma that is in close approximity to the 
minimum detectable heparin concentration in a testing plasma. Therefore, incubating 
ground non-heparinized pericardium tissues did not resulted in a loss of factor Xa activity 
as measured by clotting time or chromogenic factor Xa substrate assay. 	The 
neutralization of factor Xa occurred exceedingly only in plasma containing ground 
heparinized pericardium tissues. According to the clotting method, clotting time for 
ground heparinized pericardium tissues was excessively higher in comparison with 
plasma containing non-heparinized tissues. 
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The estimated heparin content (Units heparin per gram dried tissues) in 
pericardium tissues according to the clotting time and chromogenic factor Xa substrate 
assay showed that heparin content varied in Shelhigh's pericardium tissues (Table IV). 
The results obtained were intriguing, since heparinization of the pericardium tissues was 
performed, using standard manufacturing procedures. However, there exist several 
reasons to explain the lack of heparin content consistency in the pericardium tissues. 
First, the degree of how fine each tissue was ground varied from tissue to tissue as 
mentioned before. Second, each pericardium tissue may have different heparin content 
on its matrix or different heparin diffusion rate. 	This implied that Shelhigh's 
heparinization process or binding of heparin onto tissues matrix may not be conforming 
to homogeneity. Therefore, the process might need to improve to ensure the amount of 
heparin immobilized on tissue matrix remains the same for all of the tissues and for the 
diffusivity of heparin to be also the same for all the tissues. 
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Table IV. Estimated Heparin Content in Biological Pericardium Tissues 







(Units/ gm dried 
tissues) 
961016 .2258 3.404 3.245 
970917 .1472 1.809 1.918 
960203 .2745 2.143 2.640 
970909 .2017 5.929 2.944 
970925 .1431 1.936 1.958 
970814 .1008 2.428 2.055 
961211 .1252 2.221 1.819 
960401 .2842 2.139 1.871 
960401 .2581 6.726 6.393 
960401 .2064 8.481 7.831 
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Table IV. (Cont.) 
970811 .2083 7.403 7.153 
941213 .2251 10.314 9.605 
931206 .2786 4.212 3.482 
950222 .2101 25.586 25.507 
970929 (16) .179 24.203 20.581 
970929 (15) .2185 12.985 11.731 
970124 .2011 2.325 1.989 
940901 .1988 8.6076 7.736 
960215 .3446 96.143 93.407 
Control 1 .1711 .4425 
Control 2 .2084 .5783 .6948 
Control 3 .1816 .9104 .8877 
Control 4 .192 .8611 .8396 
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3.4 Discussions 
The aims of this study were to evaluate whether heparin leached from Shethigh' s 
heparinized pericardium tissues when quarantined for a long shelflife; whether these 
tissue have thromboresistance properties when in contact with plasma and to estimate 
heparin content in the tissues. From the results obtained, it can be concluded that heparin 
leaching from Shelhigh's pericardium tissues is negligible and these tissues have 
thromboresistance characteristics when in contact with plasma. Accordingly, solutions of 
quarantined pericardium tissues at room temperature did not have enough heparin to 
accelerate the inactivation of factor Xa, thus prolonging plasma clotting time. 
In the work present here, when heparinized pericardium tissues were removed 
from storage solution, washed with PBS pH 7.4 and incubated at 37°C . Heparin was 
released from the heparinized biological tissues to accelerate the neutralization of factor 
Xa, therefore, prolonging the plasma clotting time. Factor Xa inactivation occurred in the 
presence of heparinized pericardium tissues but not in the presence of non-heparinized 
tissues. Therefore, when Shelhigh's heparinized pericardium tissues are implanted, the 
tissues should have blood compatibility properties. The heparin from the heparinized 
biological pericardium tissues is slow released, but the amount of heparin is sufficient in 
creating a heparin microenvironment to procure thromboresistance properties. 
Since heparin in the biological pericardium tissues is not surface-bound as in the 
immobilization of heparin on polymer surfaces. 	To estimate heparin content on 
biological pericardium tissues, the tissues had to be dried, ground and homogenized with 
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plasma. Diffusion of heparin and lack of homogeneity in the tissues ground are 
presumed to be major reason as to why heparin content estimated on the pericardium 
tissues varied (Table IV). 	Nonetheless, when ground heparinized tissues were 
homogenized with plasma and incubated at 37°CC , the apparent loss of factor Xa activity 
as measured by the clotting time and chromogenic factor Xa method was attributed by the 
trace amounts of heparin found in plasma. The inactivation of the clotting factor Xa was 
proportional to the amount of heparin present in the plasma. 	Furthermore, the 
inactivation of factor Xa increased even more when the tissues were ground to fine 
powder, mixed thoroughly and allowed to soak overnight in the plasma before incubating 
at the incubation temperature (i.e. 37°C). Therefore, the heparin content estimated for a 
tissue depends on the length of incubation period allowed and how fine a tissue was 
ground. Of these two factors, only the length of incubation period was more apt to 
control. The degree of how fine a tissue may be ground was observed to vary from tissue 
to tissue, although all of the tissues were pericardium, dried and ground under similar 
conditions. Consequently of this observation, it was concluded that the estimation of 
heparin content in heparinized pericardium tissue may not be very reproducible. To 
resolve this problem, alternative attempts were made in order to make the estimation of 
heparin content in pericardium tissues more reproducible. One such attempt was using a 
meat grinder to grind the tissues while wet, instead of drying the tissues in an oven. 
However, such attempts failed because the tissues may have undergone before, during or 
after the tissues are heparinized. 
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Therefore, the meat grinder was not able to cut the tissues into small fine pieces. 
As a result, it was concluded the best method for the present investigation was to dry 
large of pericardium tissues in an oven at 60°C for approximately 2-3 days. Then, 
ground the tissue to very fine powder, and this was observed to vary from tissue to tissue. 
The method of toluidine blue (10) was also used to estimate heparin content in 
homogenized solution. However, it was observed when the homogenized solution was 
added to an equal volume of an aqueous toluidine blue solution, the tint of the dye 
solution did not change color (i.e. from blue to red violet for high heparin concentration 
or intermediate shades of purple for low heparin concentration) as prescribed by the 
protocol. APTT test was performed on similar homogenized solution after diluted with 
equal volume of normal human plasma. It was observed, that clotting time for the plasma 
increased dramatically compared with the plasma without heparin added. Although the 
APTT is a global test, it does not specifically measure heparin ability to accelerate the 
inactivation of clotting factors such as factor Xa or thrombin, the prolonged clotting time 
of the plasma, when mixed with the homogenized solution, indicated the presence of 
heparin in the homogenized samples. 
To test whether errors were made in the part of the experimenter or whether there 
existed some experimental flaws in the toluidine blue protocol, different heparin 
concentration in 0.9% saline solution was prepared by two members in the laboratory. 
The heparin concentration in the samples was not revealed to the experimenter, and the 
solutions were tested using the toluidine blue and APTT methods. 
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The results obtained for the heparin concentration in the 0.9 % saline solution using the 
toluidine blue and APTT method, agreed within the limits of experimental error. Thus, in 
the homogenized solution, it was concluded there existed an unknown interference(s) 
that prevents the reaction between the heparin and the aqueous toluidine dye. Soluble 
proteins or elements released from the ground heparinized pericardium tissues might have 
been the culprit that inhibits reaction between heparin in homogenized solution with 
toluidine blue dye or to a significant degree inhibits the formation of the heparin-dye 
complex. However, further studies are required in order to confirm such claims. 
CHAPTER 4 
CONCLUSIONS AND SUGGESTIONS 
The work presented here in this thesis serves as a basis for estimating heparin content in 
biological tissues. Although it was observed that the method used to estimate heparin 
content in biological pericardium tissues was not very reproducible, the objectives of the 
authors for this investigation were fulfilled. It was shown that heparin from heparinized 
pericardium tissues when quarantined for long shelflife leached very little or not at all 
into storage solution. Also shown in this study was, when Shelhigh's biological 
pericardium tissues were in contact with plasma, loss of factor Xa activity was observed. 
Thus, Shelhigh's pericardium tissues have thromboresistance characteristics. 	In 
addition, the investigation revealed heparin content on pericardium tissue varied from 
tissue to tissue, although the tissues were heparinized under similar manufacturing 
procedures and all of the heparinized pericardium tissues used for the study were dried, 
ground and incubated under similar conditions. The heparin content estimated on 
different pericardium tissues showed that the diffusitivity of heparin from the tissues may 
vary from tissue to tissue and each tissue may have different heparin content immobilized 




Therefore, future research will require one to study the diffusion rate of heparin 
from pericardium tissues incubated in plasma. In addition, since heparin is not bound 
onto the surface of biological pericardium tissues as in heparin immobilization on 
polymer surfaces, future research will also oblige one to find a way to extract 
immobilized heparin from tissues matrix after the tissues undergone fixation procedures. 
Currently, there are no known available methods to extract heparin from heparinized 
biomaterials. However, there is a method to extract or remove heparin from solution 
through the use of heparinase. But the method inactivates heparin in the solution, thus 
making heparin less susceptible to be measured using established methods. 
Nonetheless, the apparent loss of factor Xa activity as measured by the clotting 
time and the chromogenic factor Xa substrate assay demonstrated that Shelhigh's 
pericardium tissues have thromboresistance characteristics when in contact with plasma. 
Therefore, heparin activities on Shelhigh's pericardium tissues is sufficient in 
accelerating the neutralization of thrombin and factor Xa, thus able to reduce or prevent 
thrombus formation on the pericardium tissue surface when implanted. 	Explanted 
pericardium tissues are now being tested to determine whether explanted tissues from 
patients still retain blood compatibility in vitro after long implantation. 	Furthermore, 
more studies will be performed at Shelhigh Inc. to find ways to reduce variation in 
heparin content on tissues and to make the estimation of heparin content more 
reproducible and accurate. 
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